MetaVia, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on the stock and has a $20.00 price target.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Andrew Fein has given his Buy rating due to a combination of factors, primarily centered on the evolving profile of DA-1726 as it advances through clinical development. The successful escalation to the 48 mg and 64 mg dose levels without major tolerability issues, combined with the upcoming 4Q26, 16-week data readout, positions DA-1726 at a potential inflection point where sustained and deepening weight loss, along with incremental efficacy at 64 mg, could materially enhance MetaVia’s value proposition.

Fein’s conviction is further supported by emerging differentiation signals from recent EASL and ADA presentations, which suggest a broader metabolic and hepatic benefit beyond weight reduction alone, including improvements in liver-related measures and dose-proportional exposure at higher doses. With the price target reaffirmed at $20, he views a successful 4Q26 readout—showing clear dose response, manageable gastrointestinal tolerability, and consistent liver signals—as capable of establishing DA-1726 as a distinct obesity-plus-MASH asset and providing a robust foundation for the planned Phase 2 trials, thereby justifying a Buy recommendation on MTVA.

According to TipRanks, Fein is a 5-star analyst with an average return of 25.5% and a 53.85% success rate. Fein covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, MetaVia, and Amylyx Pharmaceuticals Inc.